P3 Health Partners Inc. (PIII) - Dilution Analysis

10-K filing | 3.3M shares outstanding

10-Q filing | 3.3M shares outstanding

8-K filing: P3 Health Group, LLC, a subsidiary of P3 Health Partners Inc., entered into a financing transaction with VBC Growth SPV 5, LLC, consisting of an unsecured promissory note for up to $70.0 million and warrants to purchase 1,430,281 shares of Class A Common Stock at an exercise price of $7.39 per share.

10-Q filing | 3.3M shares outstanding

8-K filing: Stock split 1-for-50 | Outstanding: 146,998,000 → 2,939,960

10-K filing | 147.0M shares outstanding

8-K filing: P3 Health Group, LLC, a subsidiary of P3 Health Partners Inc., entered into a financing transaction with VBC Growth SPV 4, LLC, consisting of an unsecured promissory note and warrants to purchase 71,406,480 shares of Class A Common Stock at an exercise price of $0.2068 per share, pending stockholder approval.

8-K filing: P3 Health Group, LLC, a subsidiary of P3 Health Partners Inc., entered into a financing transaction with VBC Growth SPV 3, LLC, consisting of an unsecured promissory note and warrants to purchase 71,406,480 shares of Class A Common Stock at an exercise price of $0.2137 per share.

10-Q filing | 161.9M shares outstanding

10-Q filing | 161.8M shares outstanding

S-3 filing: This is an S-3 filing for the resale of up to 134,768,734 shares of Class A Common Stock by selling stockholders, including shares presently issued and outstanding, shares issuable upon exercise of common warrants, and shares issuable upon exercise of pre-funded warrants.

8-K filing: P3 Health Partners Inc. issued approximately 67.4 million units at a price of approximately $0.6270 per unit, with each unit consisting of one share of Class A Common Stock and a warrant to purchase one share of Common Stock at an exercise price of $0.5020, for aggregate gross proceeds of approximately $42.2 million. ($84.4M proceeds)

8-K filing: P3 Health Partners Inc. entered into a Securities Purchase Agreement to issue approximately 67.4 million units at $0.6270 per unit, with each unit consisting of one share of Class A Common Stock and a warrant to purchase one share of Common Stock at an exercise price of $0.5020, resulting in aggregate gross proceeds of approximately $42.2 million. ($42.2M proceeds)

10-Q filing | 118.9M shares outstanding

10-K filing | 119.3M shares outstanding

S-3 filing: P3 Health Partners Inc. is offering up to $250,000,000 in the aggregate of Class A Common Stock, Preferred Stock, and Debt Securities from time to time in one or more offerings. A portion of the offering includes shares of Class A common stock having an aggregate offering price of up to $75,000,000 via an "at the market offering" through agent Jefferies to fund continued growth and for general corporate purposes.

POS AM filing: This is a POS AM filing for the resale of up to 136,685,830 shares of Class A Common Stock by selling stockholders.

POS AM filing: This is a POS AM filing for the resale of Class A Common Stock and Warrants, as well as the issuance of Class A Common Stock upon warrant exercise.

10-Q filing | 114.2M shares outstanding

10-Q filing | 107.5M shares outstanding

POS AM filing: This prospectus relates to the resale of shares of Class A Common Stock and warrants by selling securityholders, as well as the issuance of shares upon exercise of warrants.

S-1/A filing: This prospectus relates to the proposed resale or other disposition by the Selling Stockholders of up to an aggregate of 139,847,114 shares of Class A Common Stock.

10-Q filing | 110.7M shares outstanding

S-1 filing: This S-1 filing relates to the proposed resale of up to 139,847,114 shares of Class A Common Stock by Selling Stockholders.

POS AM filing: This prospectus relates to the resale of shares of Class A Common Stock and warrants by selling securityholders and the issuance of shares of Class A Common Stock upon exercise of warrants.

8-K filing: P3 Health Partners Inc. issued 69,157,145 shares of Class A Common Stock, warrants to purchase 59,934,479 shares of Common Stock, and pre-funded warrants to purchase 10,755,490 shares of Common Stock in a private placement for aggregate gross proceeds of approximately $89.5 million. ($89.5M proceeds)

8-K filing: P3 Health Partners Inc. entered into a Securities Purchase Agreement to issue approximately 69.2 million shares of Class A Common Stock, warrants to purchase approximately 59.9 million shares, and pre-funded warrants to purchase approximately 10.8 million shares for aggregate gross proceeds of approximately $89.5 million. ($0.0M proceeds)

10-K filing | 41.6M shares outstanding

8-K filing: P3 Health Partners, LLC, a subsidiary of P3 Health Partners Inc., entered into a financing transaction with VBC Growth SPV LLC, consisting of an unsecured promissory note and warrants to purchase shares of Class A Common Stock.

10-Q filing | 41.6M shares outstanding

POS AM filing: This prospectus relates to the resale of shares of Class A Common Stock and warrants by selling securityholders and the issuance of shares of Class A Common Stock upon exercise of warrants.

10-K filing | 41.6M shares outstanding

10-Q filing | 41.6M shares outstanding

10-Q filing | 41.6M shares outstanding

S-1 filing: This S-1 filing relates to the resale of shares of Class A common stock and warrants by selling securityholders, as well as the issuance of shares upon exercise of warrants.

10-Q filing | 40.4M shares outstanding

10-Q filing | 32.5M shares outstanding

10-Q filing | 1.8M shares outstanding

S-1/A filing: Initial public offering of 27,500,000 units at $10.00 per unit, each unit consisting of one share of Class A common stock and one-third of one redeemable warrant.

S-1/A filing: Foresight Acquisition Corp. is offering 27,500,000 units at $10.00 per unit, each consisting of one share of Class A common stock and one-third of one redeemable warrant, in an initial public offering.

S-1 filing: Foresight Acquisition Corp. is offering 27,500,000 units at $10.00 per unit in an initial public offering. Each unit consists of one share of Class A common stock and one-third of one redeemable warrant. The underwriters have a 45-day option to purchase up to an additional 4,125,000 units.